Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Medical treatment of dystonia.

Identifieur interne : 000917 ( Main/Exploration ); précédent : 000916; suivant : 000918

Medical treatment of dystonia.

Auteurs : Joseph Jankovic [États-Unis]

Source :

RBID : pubmed:23893456

English descriptors

Abstract

Medications such as anticholinergic drugs, dopamine modulators, baclofen, muscle relaxants, and other pharmacologic agents have been used for a long time to treat dystonia, but the introduction of botulinum toxin and deep brain stimulation clearly revolutionized the symptomatic treatment of this neurological movement disorder. Therapy of dystonia can be divided into the following categories: (1) physical, supportive, and ancillary therapy; (2) pharmacologic treatment; (3) chemodenervation with botulinum toxin; and (4) peripheral and central surgery (deep brain stimulation). Except in some cases of secondary dystonia, pathogenesis-targeted or disease-modifying therapy is currently not available. This review focuses on evidence-based medical treatment of dystonia, highlighting recent advances, with emphasis on individualized approach. © 2013 Movement Disorder Society.

DOI: 10.1002/mds.25552
PubMed: 23893456


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Medical treatment of dystonia.</title>
<author>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2">
<nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. josephj@bcm.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea>
<placeName>
<region type="state">Texas</region>
</placeName>
<placeName>
<settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="doi">10.1002/mds.25552</idno>
<idno type="RBID">pubmed:23893456</idno>
<idno type="pmid">23893456</idno>
<idno type="wicri:Area/PubMed/Corpus">000801</idno>
<idno type="wicri:Area/PubMed/Curation">000801</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000932</idno>
<idno type="wicri:Area/Ncbi/Merge">003C95</idno>
<idno type="wicri:Area/Ncbi/Curation">003C95</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003C95</idno>
<idno type="wicri:Area/Main/Merge">000917</idno>
<idno type="wicri:Area/Main/Curation">000917</idno>
<idno type="wicri:Area/Main/Exploration">000917</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Medical treatment of dystonia.</title>
<author>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2">
<nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. josephj@bcm.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea>
<placeName>
<region type="state">Texas</region>
</placeName>
<placeName>
<settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Baclofen (therapeutic use)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Cholinergic Antagonists (therapeutic use)</term>
<term>Disease Management</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dystonia (physiopathology)</term>
<term>Dystonia (therapy)</term>
<term>Humans</term>
<term>Muscle Relaxants, Central (therapeutic use)</term>
<term>Physical Therapy Modalities</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Dyskinesia Agents</term>
<term>Baclofen</term>
<term>Botulinum Toxins</term>
<term>Cholinergic Antagonists</term>
<term>Dopamine Agents</term>
<term>Muscle Relaxants, Central</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Dystonia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Disease Management</term>
<term>Humans</term>
<term>Physical Therapy Modalities</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Medications such as anticholinergic drugs, dopamine modulators, baclofen, muscle relaxants, and other pharmacologic agents have been used for a long time to treat dystonia, but the introduction of botulinum toxin and deep brain stimulation clearly revolutionized the symptomatic treatment of this neurological movement disorder. Therapy of dystonia can be divided into the following categories: (1) physical, supportive, and ancillary therapy; (2) pharmacologic treatment; (3) chemodenervation with botulinum toxin; and (4) peripheral and central surgery (deep brain stimulation). Except in some cases of secondary dystonia, pathogenesis-targeted or disease-modifying therapy is currently not available. This review focuses on evidence-based medical treatment of dystonia, highlighting recent advances, with emphasis on individualized approach. © 2013 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Texas</li>
</region>
<settlement>
<li>Houston</li>
</settlement>
<orgName>
<li>Baylor College of Medicine</li>
</orgName>
</list>
<tree>
<country name="États-Unis">
<region name="Texas">
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000917 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000917 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23893456
   |texte=   Medical treatment of dystonia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23893456" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024